Literature DB >> 18042215

Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder.

Leonard Derogatis1, Anita Clayton, Diane Lewis-D'Agostino, Glen Wunderlich, Yali Fu.   

Abstract

INTRODUCTION: The concept of sexually related personal distress is currently central to the diagnosis of all female sexual dysfunctions (FSD). In the current study, we have focused on validating a slightly revised version of the Female Sexual Distress Scale (FSDS), the FSDS-Revised (FSDS-R), to enhance the sensitivity of the instrument with patients suffering from hypoactive sexual desire disorder (HSDD). In addition, we have attempted to extend the validation generalizability of the scale by demonstrating that both instruments possess reliability and discriminative validity in premenopausal women with HSDD. AIM: To assess the validity of the revised version of the FSDS, the FSDS-R, for measuring sexual distress in women with HSDD.
METHODS: A prospective methodological study carried out at 27 centers in North America enrolled 296 women aged 18-50 years with HSDD, another female sexual dysfunction (FSD), or no FSD. The subjects completed the FSDS-R at baseline, day 7, and day 28, with a 30-day recall at baseline and with a 7-day recall on days 7 and 28. MAIN OUTCOME MEASURES: Receiver operating characteristic (ROC) analyses of FSDS, FSDS-R, and FSDS-R item 13 were used for the differentiation of HSDD from no FSD, while intraclass correlation coefficient (ICC) was used to estimate test-retest reliability. Cronbach's coefficient alpha was used to measure the internal consistency of the FSDS-R and Pearson's correlation coefficient to assess FSDS, FSDS-R, and FSDS-R item 13 with different recall periods (7 and 30 days).
RESULTS: Mean total FSDS, FSDS-R, and FSDS-R item 13 scores with either recall period were significantly higher (P < 0.0001) in women with FSD or HSDD than in women with no FSD, showing both tests had discriminant validity. ROC analysis confirmed these findings, while an ICC of >0.74 showed the test-retest reliability of both scales, including FSDS-R item 13 alone, and Cronbach's coefficient alpha of >0.86 confirmed the internal consistency of both tests.
CONCLUSIONS: Consistent with the FSDS, the FSDS-R demonstrated good discriminant validity, high test-retest reliability, and a high degree of internal consistency in measuring sexually related personal distress in women with HSDD. FSDS-R item 13 alone also demonstrated good discriminant validity and test-retest reliability.

Entities:  

Mesh:

Year:  2007        PMID: 18042215     DOI: 10.1111/j.1743-6109.2007.00672.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  82 in total

1.  Sexual Function among Women in Midlife: Findings from the Nurses' Health Study II.

Authors:  Christiana von Hippel; Avanti Adhia; Shoshana Rosenberg; S Bryn Austin; Ann Partridge; Rulla Tamimi
Journal:  Womens Health Issues       Date:  2019-05-23

2.  Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial.

Authors:  Susan J Diem; Katherine A Guthrie; Caroline M Mitchell; Susan D Reed; Joseph C Larson; Kristine E Ensrud; Andrea Z LaCroix
Journal:  Menopause       Date:  2018-10       Impact factor: 2.953

3.  Quality improvement in sexual health care for oncology patients: a Canadian multidisciplinary clinic experience.

Authors:  Adele Duimering; Lauren M Walker; Jill Turner; Elisha Andrews-Lepine; Amy Driga; Ashley Ayume; John W Robinson; Ericka Wiebe
Journal:  Support Care Cancer       Date:  2019-08-19       Impact factor: 3.603

4.  Prevalence and correlates of sexual morbidity in long-term breast cancer survivors.

Authors:  Greer A Raggio; Meghan L Butryn; Danielle Arigo; Renee Mikorski; Steven C Palmer
Journal:  Psychol Health       Date:  2014-01-28

5.  A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy.

Authors:  Pragati Advani; Abenaa M Brewster; George P Baum; Leslie R Schover
Journal:  J Cancer Surviv       Date:  2017-02-22       Impact factor: 4.442

6.  Sexual function and sex hormones in breast cancer patients.

Authors:  Antonio Gambardella; Daniela Esposito; Giacomo Accardo; Marianna Taddeo; Antonietta Letizia; Rossella Tagliafierro; Katherine Esposito; Daniela Pasquali
Journal:  Endocrine       Date:  2017-11-14       Impact factor: 3.633

7.  Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.

Authors:  Leslie R Schover; George P Baum; Lisa A Fuson; Abenaa Brewster; Amal Melhem-Bertrandt
Journal:  J Sex Med       Date:  2014-08-21       Impact factor: 3.802

8.  Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial.

Authors:  Grace Huang; Shehzad Basaria; Thomas G Travison; Matthew H Ho; Maithili Davda; Norman A Mazer; Renee Miciek; Philip E Knapp; Anqi Zhang; Lauren Collins; Monica Ursino; Erica Appleman; Connie Dzekov; Helene Stroh; Miranda Ouellette; Tyler Rundell; Merilyn Baby; Narender N Bhatia; Omid Khorram; Theodore Friedman; Thomas W Storer; Shalender Bhasin
Journal:  Menopause       Date:  2014-06       Impact factor: 2.953

Review 9.  Evaluation and treatment of female sexual disorders.

Authors:  Sheryl Kingsberg; Stanley E Althof
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-05

10.  Bullying Victimization and Sexual Wellbeing in Sexually Active Heterosexual, Cisgender and Sexual/Gender Minority Adolescents: The Mediating Role of Emotion Regulation.

Authors:  Alice Girouard; Jacinthe Dion; Beáta Bőthe; Lucia O'Sullivan; Sophie Bergeron
Journal:  J Youth Adolesc       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.